Prandin
Product Images NDC 68151-3566

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Prandin (NDC 68151-3566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig. 1 (Structural Formula of Prandin)

Chemical structure of the active ingredient for Prandin, showing molecular connectivity including aromatic rings, carbonyl groups, and other functional groups typical for its chemical classification.*

FDA Label Image

Fig. 2 (Prandin Pioglitazone Combination Study)

A line graph showing the change in HbA1c percentage over treatment weeks (0 to 24) for three groups: Prandin + Pioglitazone, Prandin alone, and Pioglitazone alone. The vertical axis represents change in HbA1c (%) from -2.0 to 0.5, illustrating treatment efficacy trends over time.*

FDA Label Image

Label Image (Lbl681513566)

Label for Prandin 1 mg tablet showing the active ingredient repaglinide. The label indicates manufacturing by Novo Nordisk, batch lot number A201005, and an expiration date of 08/14. It also includes a barcode and states Rx only. The labeler is Carilion Materials Management.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.